146 related articles for article (PubMed ID: 38291414)
1. T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain as a promising immune checkpoint target for the treatment of SLE.
Zhao J; Li L; Feng X; Fan X; Yin H; Lu Q
Lupus; 2024 Mar; 33(3):209-216. PubMed ID: 38291414
[TBL] [Abstract][Full Text] [Related]
2. TIGIT-Fc fusion protein alleviates murine lupus nephritis through the regulation of SPI-B-PAX5-XBP1 axis-mediated B-cell differentiation.
Zhao J; Li L; Feng X; Gao C; Gao L; Zhan Y; Wang Z; Zhao M; Yin H; Lu Q
J Autoimmun; 2023 Sep; 139():103087. PubMed ID: 37481835
[TBL] [Abstract][Full Text] [Related]
3. TIGIT: An emerging immune checkpoint target for immunotherapy in autoimmune disease and cancer.
Zhao J; Li L; Yin H; Feng X; Lu Q
Int Immunopharmacol; 2023 Jul; 120():110358. PubMed ID: 37262959
[TBL] [Abstract][Full Text] [Related]
4. Synthetic studies on the extracellular domain of the T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) using Trt-K
Iwamoto N; Sasaki J; Ohno S; Aoki K; Usui Y; Inuki S; Ohno H; Oishi S
Bioorg Med Chem; 2024 Feb; 99():117585. PubMed ID: 38219557
[TBL] [Abstract][Full Text] [Related]
5. TIGIT signalling pathway negatively regulates CD4
Mao L; Hou H; Wu S; Zhou Y; Wang J; Yu J; Wu X; Lu Y; Mao L; Bosco MJ; Wang F; Sun Z
Immunology; 2017 Jul; 151(3):280-290. PubMed ID: 28108989
[TBL] [Abstract][Full Text] [Related]
6. Treatment of murine lupus with TIGIT-Ig.
Liu S; Sun L; Wang C; Cui Y; Ling Y; Li T; Lin F; Fu W; Ding M; Zhang S; Lei C; Hu S
Clin Immunol; 2019 Jun; 203():72-80. PubMed ID: 31005675
[TBL] [Abstract][Full Text] [Related]
7. TIGIT as a Promising Therapeutic Target in Autoimmune Diseases.
Yue C; Gao S; Li S; Xing Z; Qian H; Hu Y; Wang W; Hua C
Front Immunol; 2022; 13():911919. PubMed ID: 35720417
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Molecule TIGIT Regulates Kidney T Cell Functions and Contributes to AKI.
Noel S; Lee K; Gharaie S; Kurzhagen JT; Pierorazio PM; Arend LJ; Kuchroo VK; Cahan P; Rabb H
J Am Soc Nephrol; 2023 May; 34(5):755-771. PubMed ID: 36747315
[TBL] [Abstract][Full Text] [Related]
9. Expression of T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain on CD4
Kurita M; Yoshihara Y; Ishiuji Y; Chihara M; Ishiji T; Asahina A; Yanaba K
J Dermatol; 2019 Jan; 46(1):37-42. PubMed ID: 30402886
[TBL] [Abstract][Full Text] [Related]
10. Gene of the month: T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT).
Bolm L; Petruch N; Sivakumar S; Annels NE; Frampton AE
J Clin Pathol; 2022 Apr; 75(4):217-221. PubMed ID: 35058314
[TBL] [Abstract][Full Text] [Related]
11. T-cell Immunoglobulin and ITIM Domain Contributes to CD8
Song Y; Wang B; Song R; Hao Y; Wang D; Li Y; Jiang Y; Xu L; Ma Y; Zheng H; Kong Y; Zeng H
Aging Cell; 2018 Apr; 17(2):. PubMed ID: 29349889
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of signal regulatory protein alpha and T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain expression in undifferentiated pleomorphic sarcoma.
Ishihara S; Iwasaki T; Kohashi K; Kawaguchi K; Toda Y; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Nakashima Y; Oda Y
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2425-2436. PubMed ID: 35737088
[TBL] [Abstract][Full Text] [Related]
13. The Role of Immune Checkpoint Receptors in Regulating Immune Reactivity in Lupus.
Lu KL; Wu MY; Wang CH; Wang CW; Hung SI; Chung WH; Chen CB
Cells; 2019 Oct; 8(10):. PubMed ID: 31597242
[TBL] [Abstract][Full Text] [Related]
14. Expression of T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains (TIGIT) in anaplastic thyroid carcinoma.
Nakazawa T; Nagasaka T; Yoshida K; Hasegawa A; Guo F; Wu D; Hiroshima K; Katoh R
BMC Endocr Disord; 2022 Aug; 22(1):204. PubMed ID: 35971106
[TBL] [Abstract][Full Text] [Related]
15. HTLV-1 bZIP Factor Impairs Anti-viral Immunity by Inducing Co-inhibitory Molecule, T Cell Immunoglobulin and ITIM Domain (TIGIT).
Yasuma K; Yasunaga J; Takemoto K; Sugata K; Mitobe Y; Takenouchi N; Nakagawa M; Suzuki Y; Matsuoka M
PLoS Pathog; 2016 Jan; 12(1):e1005372. PubMed ID: 26735971
[TBL] [Abstract][Full Text] [Related]
16. PD-L1-expressing neutrophils as a novel indicator to assess disease activity and severity of systemic lupus erythematosus.
Luo Q; Huang Z; Ye J; Deng Y; Fang L; Li X; Guo Y; Jiang H; Ju B; Huang Q; Li J
Arthritis Res Ther; 2016 Feb; 18():47. PubMed ID: 26867643
[TBL] [Abstract][Full Text] [Related]
17. DNAM-1 versus TIGIT: competitive roles in tumor immunity and inflammatory responses.
Shibuya A; Shibuya K
Int Immunol; 2021 Nov; 33(12):687-692. PubMed ID: 34694361
[TBL] [Abstract][Full Text] [Related]
18. Elevated expression of TIGIT on CD3
Luo Q; Ye J; Zeng L; Li X; Fang L; Ju B; Huang Z; Li J
Allergy Asthma Clin Immunol; 2017; 13():15. PubMed ID: 28261278
[TBL] [Abstract][Full Text] [Related]
19. Engineered PD-1/TIGIT dual-activating cell-membrane nanoparticles with dexamethasone act synergistically to shape the effector T cell/Treg balance and alleviate systemic lupus erythematosus.
Guo Q; Chen C; Wu Z; Zhang W; Wang L; Yu J; Li L; Zhang J; Duan Y
Biomaterials; 2022 Jun; 285():121517. PubMed ID: 35504179
[TBL] [Abstract][Full Text] [Related]
20. Decreased expression of TIGIT in NK cells correlates negatively with disease activity in systemic lupus erythematosus.
Luo Q; Li X; Fu B; Zhang L; Deng Z; Qing C; Su R; Xu J; Guo Y; Huang Z; Li J
Int J Clin Exp Pathol; 2018; 11(5):2408-2418. PubMed ID: 31938353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
